MedPath

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Phase 3
Conditions
Brain and Central Nervous System Tumors
Registration Number
NCT00053872
Lead Sponsor
University of Leicester
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways with combination chemotherapy may kill any remaining tumor cells following surgery. It is not yet known which radiation therapy regimen combined with combination chemotherapy is more effective in treating medulloblastoma.

PURPOSE: Randomized phase III trial to compare different radiation therapy regimens plus combination chemotherapy in treating children who have undergone surgery for medulloblastoma.

Detailed Description

OBJECTIVES:

* Compare the event-free survival rate in pediatric patients with standard-risk medulloblastoma treated with conventional vs hyperfractionated radiotherapy and vincristine followed by maintenance with cisplatin, lomustine, and vincristine.

* Compare the overall survival of patients treated with these regimens.

* Compare the pattern of relapse, especially local relapse (tumor bed or posterior fossa outside tumor bed), in patients treated with these regimens.

* Determine the toxicity of surgery and whether there are identifiable factors that correlate with toxicity in these patients.

* Determine the impact of any surgical complications on commencement of adjuvant therapy and event-free survival of these patients.

* Compare late sequelae, in terms of health status, endocrine deficiencies, and hearing loss, in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to country. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Within 28-40 days after surgical resection, patients undergo conventional fractionated radiotherapy once daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine IV once weekly for 8 weeks.

* Arm II: Beginning as in arm I, patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine as in arm I.

* Maintenance chemotherapy:Six weeks after completion of radiotherapy, all patients receive cisplatin IV over 6 hours and oral lomustine on day 1 and vincristine IV on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 courses.

Patients are followed at least every 6 months for 3 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 316 patients (158 per treatment arm) will be accrued for this study within 4 years.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
316
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of event-free survival at 3 years
Secondary Outcome Measures
NameTimeMethod
Comparison of overall survival
Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])
Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies
Toxicity of neurosurgery

Trial Locations

Locations (8)

Institut Curie Hopital

🇫🇷

Paris, France

Universitaets - Kinderklinik Wuerzburg

🇩🇪

Wuerzburg, Germany

Academisch Medisch Centrum at University of Amsterdam

🇳🇱

Amsterdam, Netherlands

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Ospedale Infantile Regina Margherita

🇮🇹

Turin, Italy

Ostra Sjukhuset

🇸🇪

Gothenburg, Sweden

Hospital de Cruces

🇪🇸

Vizcaya, Spain

Royal Liverpool Children's Hospital, Alder Hey

🇬🇧

Liverpool, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath